Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Melanoma

  Free Subscription


Articles published in Melanoma Res

Retrieve available abstracts of 194 articles:
HTML format
Text format



Single Articles


    June 2017
  1. WANDLER A, Riber-Hansen R, Hager H, Hamilton-Dutoit SJ, et al
    Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
    Melanoma Res. 2017 Jun 13. doi: 10.1097/CMR.0000000000000374.
    PubMed     Text format     Abstract available


  2. TOMIZUKA T, Namikawa K, Higashi T
    Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013.
    Melanoma Res. 2017 Jun 12. doi: 10.1097/CMR.0000000000000375.
    PubMed     Text format     Abstract available


  3. SOARES CD, Borges CF, Sena-Filho M, Almeida OP, et al
    Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
    Melanoma Res. 2017 Jun 9. doi: 10.1097/CMR.0000000000000368.
    PubMed     Text format     Abstract available


  4. DAVICK JJ, Wick MR, Gru AA
    Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.
    Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000371.
    PubMed     Text format     Abstract available


  5. GIUDICE G, Robusto F, Vestita M, Annoscia P, et al
    Single-stage excision and sentinel lymph node biopsy in cutaneous melanoma in selected patients: a retrospective case-control study.
    Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000370.
    PubMed     Text format     Abstract available


  6. WANG Y, Wen XZ, Ba HJ, Li DD, et al
    A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers.
    Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000365.
    PubMed     Text format     Abstract available


    May 2017
  7. FURDOVA A, Sramka M, Chorvath M, Kralik G, et al
    Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma.
    Melanoma Res. 2017 May 17. doi: 10.1097/CMR.0000000000000364.
    PubMed     Text format     Abstract available


  8. MANGANA J, Cheng PF, Kaufmann C, Amann VC, et al
    Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
    Melanoma Res. 2017 May 15. doi: 10.1097/CMR.0000000000000359.
    PubMed     Text format     Abstract available


  9. GUADAGNI S, Fiorentini G, Clementi M, Palumbo G, et al
    MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study.
    Melanoma Res. 2017 May 10. doi: 10.1097/CMR.0000000000000367.
    PubMed     Text format     Abstract available


  10. LAKHTER AJ, Naidu SR
    Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells.
    Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000363.
    PubMed     Text format     Abstract available


  11. HOLTKAMP LHJ, Read RL, Emmett L, Thompson JF, et al
    Futility of imaging to stage melanoma patients with a positive sentinel lymph node.
    Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000362.
    PubMed     Text format     Abstract available


  12. STABLER S, Becquart C, Dumezy F, Terriou L, et al
    Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma.
    Melanoma Res. 2017 May 3. doi: 10.1097/CMR.0000000000000354.
    PubMed     Text format     Abstract available


    April 2017
  13. MENDT M, Cardier JE
    Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.
    Melanoma Res. 2017 Apr 25. doi: 10.1097/CMR.0000000000000346.
    PubMed     Text format     Abstract available


  14. KYRGIDIS A, Lallas A, Moscarella E, Longo C, et al
    Does pregnancy influence melanoma prognosis? A meta-analysis.
    Melanoma Res. 2017 Apr 20. doi: 10.1097/CMR.0000000000000334.
    PubMed     Text format     Abstract available


  15. DIAMANTOPOULOS PT, Gaggadi M, Kassi E, Benopoulou O, et al
    Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
    Melanoma Res. 2017 Apr 17. doi: 10.1097/CMR.0000000000000355.
    PubMed     Text format     Abstract available


  16. PISCIOLI F, Pusiol T, Roncati L
    Critical points of T1 stage in primary melanoma.
    Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000357.
    PubMed     Text format    


  17. MURER C, Kranzlin-Stieger P, French LE, Dummer R, et al
    Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
    Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000358.
    PubMed     Text format     Abstract available


  18. TARHINI AA, Moschos SJ, Lin Y, Lin HM, et al
    Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-alpha2b in patients with metastatic melanoma.
    Melanoma Res. 2017 Apr 7. doi: 10.1097/CMR.0000000000000353.
    PubMed     Text format     Abstract available


  19. THOMSON CH, Cassell O, Peach H, Holloway S, et al
    Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study.
    Melanoma Res. 2017;27:121-125.
    PubMed     Text format     Abstract available


  20. ROGIERS A, Wolter P, Bechter O
    Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
    Melanoma Res. 2017;27:164-167.
    PubMed     Text format     Abstract available


    March 2017
  21. DE GIORGI V, Grazzini M, Benemei S, Marchionni N, et al
    beta-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
    Melanoma Res. 2017 Mar 24. doi: 10.1097/CMR.0000000000000317.
    PubMed     Text format     Abstract available


  22. HINTZSCHE JD, Gorden NT, Amato CM, Kim J, et al
    Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000345.
    PubMed     Text format     Abstract available


  23. LEON-FERRE RA, Kottschade LA, Block MS, McWilliams RR, et al
    Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000344.
    PubMed     Text format     Abstract available


  24. CARRERA C, Gual A, Diaz A, Puig-Butille JA, et al
    Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.
    Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000340.
    PubMed     Text format     Abstract available


  25. FALLENI M, Savi F, Tosi D, Agape E, et al
    M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
    Melanoma Res. 2017 Mar 7. doi: 10.1097/CMR.0000000000000352.
    PubMed     Text format     Abstract available


  26. FUKUDA K, Funakoshi T, Sakurai T, Nakamura Y, et al
    Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
    Melanoma Res. 2017 Mar 3. doi: 10.1097/CMR.0000000000000342.
    PubMed     Text format     Abstract available


  27. BLASIG H, Bender C, Hassel JC, Eigentler TK, et al
    Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
    Melanoma Res. 2017 Mar 2. doi: 10.1097/CMR.0000000000000341.
    PubMed     Text format     Abstract available


  28. DE GIORGI V, Gori A, Savarese I, D'Errico A, et al
    Clinical and dermoscopic features of truly amelanotic plantar melanoma.
    Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000337.
    PubMed     Text format     Abstract available


  29. LOQUAI C, Schmidtmann I, Garzarolli M, Kaatz M, et al
    Interactions from complementary and alternative medicine in patients with melanoma.
    Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000339.
    PubMed     Text format     Abstract available


    February 2017
  30. DESVIGNES C, Abirached H, Templier C, Drumez E, et al
    BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
    Melanoma Res. 2017 Feb 24. doi: 10.1097/CMR.0000000000000350.
    PubMed     Text format     Abstract available


  31. TAS F, Erturk K
    Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome.
    Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000351.
    PubMed     Text format     Abstract available


  32. VIZKELETI L, Kiss T, Koroknai V, Ecsedi S, et al
    Altered integrin expression patterns shown by microarray in human cutaneous melanoma.
    Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000322.
    PubMed     Text format     Abstract available


  33. ITCHINS M, Ascierto PA, Menzies AM, Oatley M, et al
    A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
    Melanoma Res. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343.
    PubMed     Text format     Abstract available


  34. MADU MF, Timmerman P, Wouters MW, van der Hiel B, et al
    PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
    Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000347.
    PubMed     Text format     Abstract available


  35. LI FJ, Li LM, Zhang RH, Xu C, et al
    The role of 5-hydroxymethylcytosine in melanoma.
    Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000349.
    PubMed     Text format     Abstract available


  36. TESIO V, Ribero S, Castelli L, Bassino S, et al
    Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.
    Melanoma Res. 2017 Feb 15. doi: 10.1097/CMR.0000000000000348.
    PubMed     Text format     Abstract available


  37. RIBERO S, Longo C, Specchio F, Piana S, et al
    Lymph nodes' capsular naevi are associated with high naevus count in melanoma patients: a case-control study.
    Melanoma Res. 2017 Feb 1. doi: 10.1097/CMR.0000000000000328.
    PubMed     Text format     Abstract available


    January 2017
  38. PELLEGRINI C, Maturo MG, Martorelli C, Suppa M, et al
    Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
    Melanoma Res. 2017 Jan 31. doi: 10.1097/CMR.0000000000000323.
    PubMed     Text format     Abstract available


  39. LINO-SILVA LS, Salcedo-Hernandez RA, Garcia-Perez L, Meneses-Garcia A, et al
    Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma.
    Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000333.
    PubMed     Text format     Abstract available


  40. GRAY A, Grushchak S, Mudaliar K, Kliethermes S, et al
    The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.
    Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000331.
    PubMed     Text format     Abstract available


  41. OBEID JM, Hu Y, Erdag G, Leick KM, et al
    The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?
    Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000330.
    PubMed     Text format     Abstract available


  42. OBA J, Esmaeli B, Ellerhorst JA, Lyons GR, et al
    Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.
    Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000329.
    PubMed     Text format     Abstract available


  43. LADWA R, Atkinson V
    The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000336.
    PubMed     Text format     Abstract available


  44. TAS F, Erturk K
    Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000332.
    PubMed     Text format     Abstract available


  45. DE HAAN J, Lok CA, de Groot CJ, Crijns MB, et al
    Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma.
    Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000327.
    PubMed     Text format     Abstract available


  46. LV C, Dai H, Sun M, Zhao H, et al
    Mesenchymal stem cells induce epithelial mesenchymal transition in melanoma by paracrine secretion of transforming growth factor-beta.
    Melanoma Res. 2017 Jan 5. doi: 10.1097/CMR.0000000000000325.
    PubMed     Text format     Abstract available


  47. BORRONI RG, Manganoni AM, Grassi S, Grasso M, et al
    Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
    Melanoma Res. 2017 Jan 4. doi: 10.1097/CMR.0000000000000324.
    PubMed     Text format     Abstract available


    December 2016
  48. LINO-SILVA LS, Castillo-Medina AL, Salcedo-Hernandez RA, Garcia-Perez L, et al
    Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary?
    Melanoma Res. 2016 Dec 27. doi: 10.1097/CMR.0000000000000319.
    PubMed     Text format     Abstract available


  49. MICEVIC G, Theodosakis N, Taube JM, Bosenberg MW, et al
    Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.
    Melanoma Res. 2016 Dec 16. doi: 10.1097/CMR.0000000000000315.
    PubMed     Text format     Abstract available


  50. BEHLING J, Kaes J, Munzel T, Grabbe S, et al
    New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  51. MININI R, Rohrmann S, Braun R, Korol D, et al
    Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  52. PISCIOLI F, Pusiol T, Roncati L
    Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system.
    Melanoma Res. 2016;26:636.
    PubMed     Text format    


  53. PISCIOLI F, Pusiol T, Roncati L
    Histopathological determination of thin melanomas at risk for metastasis.
    Melanoma Res. 2016;26:635.
    PubMed     Text format    


    November 2016
  54. LEONTOVICH AA, Dronca RS, Nevala WK, Thompson MA, et al
    Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    October 2016
  55. PAOLINO G, Panetta C, Cota C, Didona D, et al
    Vitamin D receptor immunohistochemistry variability in sun-exposed and non-sun-exposed melanomas.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  56. SHOUSHTARI AN, Bluth MJ, Goldman DA, Bitas C, et al
    Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  57. NGUYEN BH, Kuo J, Budiman A, Christie H, et al
    Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  58. VARTANIAN A, Baryshnikova M, Burova O, Afanasyeva D, et al
    Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  59. CHAKRAVARTI N, Ivan D, Trinh VA, Glitza IC, et al
    High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  60. LIM MS, Wang JH, Power DG, Redmond HP, et al
    Inflammatory regulation of stem-like cells in melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  61. ADAMS G, Foote M, Brown S, Burmeister B, et al
    Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  62. BOTTLAENDER L, Perier-Muzet M, Lapras V, Thomas L, et al
    Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  63. AMBER KT, Panganiban CM, Korta D, Feraudy S, et al
    A case report of bullous pemphigoid associated with a melanoma and review of the literature.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  64. MATHESON JA, Te Marvelde L, Mailer S, Speakman D, et al
    Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  65. HOAG JR, Hegde U, Zweifler R, Berwick M, et al
    Competing risks survival of older patients with metastatic cutaneous melanoma: a SEER population-based study.
    Melanoma Res. 2016;26:505-512.
    PubMed     Text format     Abstract available


    September 2016
  66. KUBECEK O, Kopecky J
    Microsatellite instability in melanoma: a comprehensive review.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  67. MIRJACIC MARTINOVIC KM, Babovic NL, Dzodic RR, Jurisic VB, et al
    Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  68. FAILING JJ, Finnes HD, Kottschade LA, Allred JB, et al
    Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  69. KARABULUT YY, Erdogan S, Sayar H, Ergen A, et al
    Primary malignant melanoma of the urinary bladder: clinical, morphological, and molecular analysis of five cases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  70. ROMAINE ST, Wells-Jordan P, de Haro T, Dave-Thakrar A, et al
    A small multimarker panel using simple immunohistochemistry methods is an adjunct to stage for cutaneous melanoma prognosis.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    August 2016
  71. DANISH HH, Patel KR, Switchenko JM, Gillespie TW, et al
    The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  72. ZOROQUIAIN P, Mayo-Goldberg E, Alghamdi S, Alhumaid S, et al
    Melanocytoma-like melanoma may be the missing link between benign and malignant uveal melanocytic lesions in humans and dogs: a comparative study.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  73. MCQUADE JL, Posada LP, Lecagoonporn S, Cain S, et al
    A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  74. FORTES C, Mastroeni S, Botta G, Boffetta P, et al
    Glutathione S-transferase M1 null genotype, household pesticides exposure and cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  75. SADHU SS, Wang S, Averineni RK, Seefeldt T, et al
    In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  76. DETRIXHE A, Libon F, Mansuy M, Nikkels-Tassoudji N, et al
    Melanoma masquerading as nonmelanocytic lesions.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  77. DE LEEDE EM, Burgmans MC, Kapiteijn E, Luyten GP, et al
    Isolated (hypoxic) hepatic perfusion with high-dose chemotherapy in patients with unresectable liver metastases of uveal melanoma: results from two experienced centres.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  78. BRUNET-POSSENTI F, Mignot S, Deschamps L, Descamps V, et al
    Antiepidermis autoantibodies induced by anti-PD-1 therapy in metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    July 2016
  79. DILLER ML, Kudchadkar RR, Delman KA, Lawson DH, et al
    Complete response to high-dose IL-2 and enhanced IFNgamma+Th17 : TREG ratio in a melanoma patient.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  80. ENNINGA EA, Nevala WK, Holtan SG, Leontovich AA, et al
    Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  81. FRANK GA, Aleksakhina SN, Zavalishina LE, Kekeyeva TV, et al
    BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  82. KUZBICKI L, Lange D, Stanek-Widera A, Chwirot BW, et al
    Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  83. OLSEN CM, Hyrich KL, Knight LL, Green AC, et al
    Melanoma risk in patients with rheumatoid arthritis treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  84. MAYER JE, Swetter SM, Miller DR, Sober AJ, et al
    Association of nevus count with prevention attitudes and behaviors before melanoma diagnosis.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  85. TAS F, Erturk K
    Presence of histological regression as a prognostic factor in cutaneous melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    June 2016
  86. FEDORENKO IV, Evernden B, Kenchappa RS, Sahebjam S, et al
    A rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  87. HERMS F, Kramkimel N, Regnier-Rosencher E, Carlotti A, et al
    Age and clear eyes are associated with an increased risk of cutaneous squamous cell carcinomas in vemurafenib-treated melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  88. WEN X, Wang Y, Ding Y, Li D, et al
    Safety of immune checkpoint inhibitors in Chinese patients with melanoma.
    Melanoma Res. 2016;26:284-9.
    PubMed     Text format     Abstract available


  89. MEHTA A, Gupta A, Hannallah F, Koshy T, et al
    Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma.
    Melanoma Res. 2016;26:319-20.
    PubMed     Text format    


    May 2016
  90. LUTTMANN N, Gratz V, Haase O, Eckey T, et al
    Rapid remission of symptomatic brain metastases in melanoma by programmed-death-receptor-1 inhibition.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  91. YANG S, Leone D, Frydenlund N, Hoang M, et al
    Frequency of telomerase reverse transcripter promoter mutations in desmoplastic melanoma subtypes: analyses of 76 cases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  92. VAN DER PLOEG IM, Madu MF, van der Hage JA, Wouters MW, et al
    Blue dye can be safely omitted in most sentinel node procedures for melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  93. KUK SK, Won CH, Lee WJ, Shin WJ, et al
    Prognostic significance of nestin in primary malignant melanoma of the oral cavity.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  94. HUGEL R, Muendlein A, Volbeding L, Drexel H, et al
    Serum levels of hepatocyte growth factor as a potential tumor marker in patients with malignant melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  95. ROGERS Z, Elliott F, Kasparian NA, Bishop DT, et al
    Psychosocial, clinical and demographic features related to worry in patients with melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  96. ESCOBAR GF, Arraes JA, Bakos L, Ashton-Prolla P, et al
    Polymorphisms in CYP19A1 and NFKB1 genes are associated with cutaneous melanoma risk in southern Brazilian patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  97. LEE SF, Atkinson V
    A case of acute paraneoplastic neurological syndrome in BRAF mutant metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    April 2016
  98. KROGH M, Christensen I, Bouwhuis M, Johansen JS, et al
    Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  99. ROMMENS K, Jegou D, De Backer H, Weyler J, et al
    Seasonal variation in cutaneous melanoma incidence, link with recent UV levels: a population-based study in Belgium (2006-2011).
    Melanoma Res. 2016;26:195-201.
    PubMed     Text format     Abstract available


  100. NGUYEN J, Bernert R, In K, Kang P, et al
    Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.
    Melanoma Res. 2016;26:125-37.
    PubMed     Text format     Abstract available


  101. PAOLINO G, Moliterni E, Lopez T, Cardone M, et al
    Serum tryptase levels in melanoma patients: first results of clinicopathological features.
    Melanoma Res. 2016;26:207-8.
    PubMed     Text format    


  102. VULTUR A, Schanstra T, Herlyn M
    The promise of 3D skin and melanoma cell bioprinting.
    Melanoma Res. 2016;26:205-6.
    PubMed     Text format    


  103. CHENG C, Yang HW, Shang JF, Li WW, et al
    Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
    Melanoma Res. 2016;26:117-24.
    PubMed     Text format     Abstract available


  104. WANG LE, Li C, Xiong P, Gershenwald JE, et al
    4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.
    Melanoma Res. 2016;26:181-7.
    PubMed     Text format     Abstract available


    March 2016
  105. SKINNER CC, McMichael EL, Jaime-Ramirez AC, Abrams ZB, et al
    Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  106. HWANG SJ, Carlos G, Wakade D, Sharma R, et al
    Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  107. JOSEPH RW, Cappel M, Tzou K, Bagaria S, et al
    Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  108. PADDOCK LE, Lu SE, Bandera EV, Rhoads GG, et al
    Skin self-examination and long-term melanoma survival.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  109. BAROUDJIAN B, Lourenco N, Pages C, Chami I, et al
    Anti-PD1-induced collagenous colitis in a melanoma patient.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  110. QASSEMYAR A, Gabert PE, Kluza J, Duquennoy-Martinot V, et al
    Patient-derived tumor xenograft strategies for informed management of patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  111. FLOUDAS CS, Chandra AB, Xu Y
    Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  112. LIN RL, Wang TJ, Joyce CJ, Mihm MC Jr, et al
    Decreased tumor-infiltrating lymphocytes in nodular melanomas compared with matched superficial spreading melanomas.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  113. WHIPPLE CA, Boni A, Fisher JL, Hampton TH, et al
    The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  114. JIANG H, Xu W, Zhang F, Wei L, et al
    Quantitative assessment of the association between XRCC1 Arg399Gln and Arg194Trp polymorphisms and risk of cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  115. ESPINOSA E, Soriano V, Malvehy J, Berrocal A, et al
    Treatment patterns of adjuvant interferon-alpha2b for high-risk melanoma: a retrospective study of the Grupo Espanol Multidisciplinar de Melanoma - Prima study.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    February 2016
  116. PATEL BG, Ahmed KA, Johnstone PA, Yu HM, et al
    Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  117. SINGH P, Kim HJ, Schwartz RA
    Superficial spreading melanoma: an analysis of 97 702 cases using the SEER database.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  118. TAS F, Bilgin E, Erturk K, Duranyildiz D, et al
    Clinical significance of serum claudin-1 levels in melanoma patients.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  119. VOIT CA, Oude Ophuis CM, Ulrich J, van Akkooi AC, et al
    Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  120. MORIARTY WF, Kim E, Gerber SA, Hammers H, et al
    Neuropilin-2 promotes melanoma growth and progression in vivo.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  121. KOTTSCHADE LA, McWilliams RR, Markovic SN, Block MS, et al
    The use of pembrolizumab for the treatment of metastatic uveal melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  122. IMREDI E, Toth B, Doma V, Barbai T, et al
    Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  123. KILIAN MM, Herwig MC, Holz FG, Tuting T, et al
    Overexpression of hepatocyte growth factor and an oncogenic CDK4 variant in mice alters corneal stroma morphology but does not lead to spontaneous ocular melanoma.
    Melanoma Res. 2016;26:89-91.
    PubMed     Text format    


  124. SLOOT S, Zager JS, Kudchadkar RR, Messina JL, et al
    BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Melanoma Res. 2016;26:83-7.
    PubMed     Text format     Abstract available


  125. SALDANHA G, Potter L, Lee YS, Watson S, et al
    MicroRNA-21 expression and its pathogenetic significance in cutaneous melanoma.
    Melanoma Res. 2016;26:21-8.
    PubMed     Text format     Abstract available


  126. PISCIOLI F, Pusiol T, Roncati L
    Diagnostic approach to melanocytic lesion of unknown malignant potential.
    Melanoma Res. 2016;26:91-2.
    PubMed     Text format    


    January 2016
  127. TODO Y, Okamoto K, Suzuki Y, Minobe S, et al
    Radicality of initial surgery for primary malignant melanoma of the vagina.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  128. CHIRIBOGA L, Meehan S, Osman I, Glick M, et al
    Endothelin-1 in the tumor microenvironment correlates with melanoma invasion.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  129. KONG BY, Micklethwaite KP, Swaminathan S, Kefford RF, et al
    Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  130. SHOUSHTARI AN, Ong LT, Schoder H, Singh-Kandah S, et al
    A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  131. GLAZER ES, Bartels PH, Lian F, Kha ST, et al
    Quantitative histopathology identifies patients with thin melanomas who are at risk for metastases.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  132. MUSTAPHA N, Mokdad-Bzeouich I, Maatouk M, Ghedira K, et al
    Antitumoral, antioxidant, and antimelanogenesis potencies of Hawthorn, a potential natural agent in the treatment of melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


    December 2015
  133. DE LIMA VAZQUEZ V, Vicente AL, Carloni A, Berardinelli G, et al
    Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  134. SEIFERT H, Fisher R, Martin-Liberal J, Edmonds K, et al
    Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  135. SHEPPARD HM, Feisst V, Chen J, Print C, et al
    AHNAK is downregulated in melanoma, predicts poor outcome, and may be required for the expression of functional cadherin-1.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  136. KOROKNAI V, Ecsedi S, Vizkeleti L, Kiss T, et al
    Genomic profiling of invasive melanoma cell lines by array comparative genomic hybridization.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  137. SCHREUER M, Meersseman G, van Den Herrewegen S, Jansen Y, et al
    Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  138. JACOBSOONE-ULRICH A, Jamme P, Alkeraye S, Dzwiniel V, et al
    Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  139. SONG H, Jing G, Wang L, Guo W, et al
    Periodic acid-Schiff-positive loops and networks as a prognostic factor in oral mucosal melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  140. JANSEN YJ, Janssens P, Hoorens A, Schreuer MS, et al
    Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib.
    Melanoma Res. 2015;25:550-554.
    PubMed     Text format     Abstract available


  141. SEVIM DG, Kiratli H
    Serum adiponectin, insulin resistance, and uveal melanoma: clinicopathological correlations.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  142. OLSEN CM, Lane SW, Green AC
    Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    November 2015
  143. CAMPAGNE C, Reyes-Gomez E, Loiodice S, Gadin S, et al
    Haplosufficiency of PAX3 for melanoma development in Tyr: NRASQ61K; Cdkn2a-/- mice allows identification and sorting of melanoma cells using a Pax3GFP reporter allele.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    October 2015
  144. LI P, Liu J
    Diagnostic value of MRI and computed tomography in anorectal malignant melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  145. EIBL-LINDNER K, Furweger C, Nentwich M, Foerster P, et al
    Robotic radiosurgery for the treatment of medium and large uveal melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  146. BANERJEE M, Lao CD, Wancata LM, Muenz DG, et al
    Implications of age and conditional survival estimates for patients with melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  147. IBRAHIM AM, Vargas CR, Koolen PG, Chuang DJ, et al
    Readability of online patient resources for melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  148. O'CONNELL EP, O'Leary DP, Fogarty K, Khan ZJ, et al
    Predictors and patterns of melanoma recurrence following a negative sentinel lymph node biopsy.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  149. CINTOLO JA, Datta J, Xu S, Gupta M, et al
    Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    September 2015
  150. SHIMIZU A, Kaira K, Yasuda M, Asao T, et al
    Decreased expression of class III beta-tubulin is associated with unfavourable prognosis in patients with malignant melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  151. RUBEGNI P, Feci L, Nami N, Burroni M, et al
    Computer-assisted melanoma diagnosis: a new integrated system.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  152. COUPS EJ, Manne SL, Stapleton JL, Tatum KL, et al
    Skin self-examination behaviors among individuals diagnosed with melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  153. ROUX J, Pages C, Malouf D, Basset Seguin N, et al
    BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  154. OLIVER DE, Patel KR, Switchenko J, Parker D, et al
    Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  155. KELLER AK, Uter W, Pfahlberg AB, Radespiel-Troger M, et al
    Replacing surrogate measures by direct quantification of ultraviolet radiation exposure in registry-based analyses of seasonality of melanoma diagnoses.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  156. BERTOLLI E, Macedo MP, Pinto CA, Damascena AS, et al
    Metastatic area ratio can help predict nonsentinel node positivity in melanoma patients.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  157. TRIOZZI PL, Aldrich W, Crabb JW, Singh AD, et al
    Spontaneous cellular and humoral tumor antigen responses in patients with uveal melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  158. DUMMER R, Schadendorf D, Ascierto PA, Larkin J, et al
    Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  159. GONZALEZ-CAO M, Mayo-de-Las-Casas C, Molina-Vila MA, De Mattos-Arruda L, et al
    BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  160. THIERAUF J, Veit JA, Affolter A, Bergmann C, et al
    Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  161. LATIMER NR, Amonkar MM, Stapelkamp C, Sun P, et al
    Adjusting for confounding effects of treatment switching in a randomized phase II study of dabrafenib plus trametinib in BRAF V600+ metastatic melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    August 2015
  162. NAFFOUJE S, Naffouje R, Bhagwandin S, Salti GI, et al
    Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  163. FILITIS DC, Rauh J, Mahalingam M
    The HGF-cMET signaling pathway in conferring stromal-induced BRAF-inhibitor resistance in melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  164. SIISKONEN H, Poukka M, Bykachev A, Tyynela-Korhonen K, et al
    Low numbers of tryptase+ and chymase+ mast cells associated with reduced survival and advanced tumor stage in melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  165. GAMBICHLER T, Scheitz R, Hoxtermann S
    Serum anti-BPAG1 autoantibody level is not a useful biomarker for cutaneous melanoma.
    Melanoma Res. 2015.
    PubMed     Text format    


  166. SALGADO CM, Basu D, Nikiforova M, Hamilton RL, et al
    Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  167. RUINI C, Manfredini M, Pellacani G, Mandel VD, et al
    Confocal microscopy characterization of BRAFV600E mutated melanomas.
    Melanoma Res. 2015;25:367-371.
    PubMed     Text format     Abstract available


    July 2015
  168. MORENO-RAMIREZ D, Ojeda-Vila T, Rios-Martin JJ, Nieto-Garcia A, et al
    Association between tumor size and Breslow's thickness in malignant melanoma: a cross-sectional, multicenter study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  169. SHIMIZU A, Kaira K, Kato M, Yasuda M, et al
    Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in cutaneous melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  170. NOGUCHI S, Mori T, Nakagawa T, Itamoto K, et al
    DNA methylation contributes toward silencing of antioncogenic microRNA-203 in human and canine melanoma cells.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  171. S AHMAD S, Qian W, Ellis S, Mason E, et al
    Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  172. BURGSTALLER-MUEHLBACHER S, Marko M, Muller C, Wendt J, et al
    Novel CDKN2A mutations in Austrian melanoma patients.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  173. JAKUB JW, Grotz TE, Jordan P, Hunter E, et al
    A pilot study of chromosomal aberrations and epigenetic changes in peripheral blood samples to identify patients with melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  174. DONINA S, Strele I, Proboka G, Auzins J, et al
    Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  175. SAROJINI S, Pecora A, Milinovikj N, Barbiere J, et al
    A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  176. LEJEUNE FJ
    The conquest of melanoma by immunotherapy.
    Melanoma Res. 2015.
    PubMed     Text format    


    June 2015
  177. DEROOSE JP, Grunhagen DJ, Eggermont AM, Verhoef C, et al
    Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  178. GOVERNA M, Caprarella E, Dalla Pozza E, Vigato E, et al
    Association of CDK4 germline and BRAF somatic mutations in a patient with multiple primary melanomas and BRAF inhibitor resistance.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  179. VAN BEEK JG, Koopmans AE, Vaarwater J, Verdijk RM, et al
    Metastatic disease in uveal melanoma: importance of a genetic profile?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  180. TOLK H, Satzger I, Mohr P, Zimmer L, et al
    Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  181. GORDON D, Gillgren P, Eloranta S, Olsson H, et al
    Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure: a retrospective population-based study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  182. JOSHUA AM, Monzon JG, Mihalcioiu C, Hogg D, et al
    A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  183. CHEVOLET I, Schreuer M, Speeckaert R, Neyns B, et al
    Systemic immune changes associated with adjuvant interferon-alpha2b-therapy in stage III melanoma patients: failure at the effector phase?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  184. YOUSAF N, Davidson M, Goode E, Thomas C, et al
    The cost of ipilimumab toxicity: a single-centre analysis.
    Melanoma Res. 2015;25:259-64.
    PubMed     Text format     Abstract available


    May 2015
  185. MINICHSDORFER C, Wasinger C, Sieczkowski E, Atil B, et al
    Tocilizumab unmasks a stage-dependent interleukin-6 component in statin-induced apoptosis of metastatic melanoma cells.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  186. NARDIN C, Puzenat E, Pretet JL, Algros MP, et al
    BRAF mutation screening in melanoma: is sentinel lymph node reliable?
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  187. ROLAND CL, Ross MI, Hall CS, Laubacher B, et al
    Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


  188. CHALOPIN B, Florenceau L, Fradin D, Labarriere N, et al
    A lineage-specific methylation pattern controls the transcription of the polycistronic mRNA coding MELOE melanoma antigens.
    Melanoma Res. 2015.
    PubMed     Text format     Abstract available


    February 2015
  189. KALTOFT B, Hainau B, Lock-Andersen J
    Melanocytic tumour with unknown malignant potential--a Danish study of 67 patients.
    Melanoma Res. 2015;25:64-7.
    PubMed     Text format     Abstract available


    October 2014
  190. RILEY PA
    Failure of fidelity of vertical transmission of epigenetic patterning as the basis of cancer.
    Melanoma Res. 2014;24:424-7.
    PubMed     Text format    


  191. ROBERT C, Thomas M, Mateus C
    MAP-kinase pathway up or down? Just look at the skin of your patients!
    Melanoma Res. 2014;24:421-3.
    PubMed     Text format    


  192. VOIT CA, van Akkooi AC, Eggermont AM, Tuttenberg A, et al
    Ultrasound diagnosis of an atypical axillary lesion.
    Melanoma Res. 2014;24:517-21.
    PubMed     Text format     Abstract available


  193. MCCORMACK CJ, Conyers RK, Scolyer RA, Kirkwood J, et al
    Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy.
    Melanoma Res. 2014;24:437-47.
    PubMed     Text format     Abstract available


  194. FORSCHNER A, Zips D, Schraml C, Rocken M, et al
    Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib.
    Melanoma Res. 2014;24:512-6.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: